-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...
A phase 3 study assessing the use pregabalin as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint to ...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with ...
November is Epilepsy Awareness Month. Many people may already be aware of the condition from its prevalence in medical dramas, but that portrayal is often exaggerated and does not fully encapsulate ...
NASHVILLE, Tennessee ―The retention rate for the antiseizure drug perampanel (Eisai Co, Ltd) is more than 70% for adult patients with epilepsy, new research shows. In early results from the PERPRISE ...
Individuals with focal onset epilepsy treated with azetukalner experienced sustained monthly seizure reduction and evidence of seizure freedom up to 48 months, according to data presented at the ...
Brain CT shows right temporal lobe epilepsy with hypometabolism. Seizures in the elderly often mimic other conditions, such as transient ischemic attack or dementia. Don't be fooled into a ...
People with epilepsy are at risk for hypertension, atrial fibrillation, and hyperlipidemia; they also have an elevated risk of heart disease. Research suggests some of this risk may be due to the ...
The Food and Drug Administration has granted 501(k) clearance to the Embrace watch for use in epilepsy patients aged ≥6 years. The smartwatch identifies generalized tonic-clonic seizures and alerts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback